Biogen Inc. (BIIB) to Release Quarterly Earnings on Tuesday
Biogen Inc. (NASDAQ:BIIB) will issue its quarterly earnings data before the market opens on Tuesday, October 24th. Analysts expect the company to announce earnings of $5.61 per share for the quarter. Biogen has set its FY17 guidance at $20.80-21.40 EPS.
Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same period in the previous year, the firm posted $5.21 EPS. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. On average, analysts expect Biogen to post $21.5 EPS for the current fiscal year and $23.31 EPS for the next fiscal year.
Shares of Biogen Inc. (BIIB) opened at 335.68 on Tuesday. The firm’s 50-day moving average is $319.52 and its 200-day moving average is $283.51. Biogen Inc. has a 12-month low of $244.28 and a 12-month high of $344.37. The company has a market capitalization of $70.97 billion, a price-to-earnings ratio of 22.03 and a beta of 0.77.
In other news, EVP Susan H. Alexander sold 4,974 shares of Biogen stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total value of $1,442,509.74. Following the completion of the transaction, the executive vice president now owns 22,258 shares of the company’s stock, valued at approximately $6,455,042.58. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Susan H. Alexander sold 7,758 shares of Biogen stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $285.00, for a total value of $2,211,030.00. Following the completion of the transaction, the executive vice president now directly owns 27,232 shares of the company’s stock, valued at approximately $7,761,120. The disclosure for this sale can be found here. 0.25% of the stock is owned by insiders.
BIIB has been the topic of a number of recent research reports. Vetr cut shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 price target on the stock. in a research report on Tuesday, August 29th. ValuEngine upgraded shares of Biogen from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Cowen and Company reiterated an “outperform” rating and set a $271.00 price target on shares of Biogen in a research report on Monday, July 3rd. Royal Bank Of Canada reiterated a “hold” rating and set a $315.00 price target on shares of Biogen in a research report on Thursday, October 5th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $310.00 price target on shares of Biogen in a research report on Tuesday, July 11th. Thirteen analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Biogen currently has an average rating of “Buy” and an average price target of $331.49.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.